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Proteopathies are a large and diverse group of human diseases that are caused by protein misfolding. Well-
known examples of proteopathies are Alzheimer’s and Parkinson’s disease, which are both linked to amyloid
fibril formation. In this issue of Chemistry & Biology, Castellano et al. (2015) describe the way to harness the
power of a protein from baker’s yeast, Hsp104, to disaggregate the fibrils.
Amyloid fibrils are highly ordered b
sheet-rich protein aggregates associated
with a large number of neurodegenera-
tive diseases but also with normal bio-
logical functions such as storage of pep-
tide hormones in secretory granules
(Greenwald and Riek, 2010). The identifi-
cation of amyloid-forming endogenous
peptides in semen and their implications
in HIV infectivity further demonstrate
the diverse functions of amyloid fibrils
(Mu¨nch et al., 2007). Despite an
increased understanding of amyloid as-
sembly both in vitro and in vivo, it has
proven difficult to find effective thera-
peutics for diseases caused by amyloid
proteins. In most neurodegenerative dis-
eases, the progression and severity of
the disease depends on the accumula-
tion of several types of misfolded species
(oligomers, protofibrils and fi-
brils) that form during the as-
sembly of amyloids. Because
these species have variable
conformations and structural
details that are not well un-
derstood, it has been chal-
lenging to develop thera-
peutics targeting all the
conformers simultaneously.
Hence, there has been a
great effort to generate thera-
peutics targeting the com-
mon structural features in
these misfolded aggregates.
One approach has been to
engineer conformational anti-
bodies that recognize oligo-
mers, protofibrils, andmature
fibrils to block toxicity and
fibril assembly (Haupt and
Fa¨ndrich, 2014; Kayed et al.,
2003).
Protein misfolding and aggregation is a
common feature of cell physiology. To
prevent the damaging effects of protein
misfolding, cells have evolved various
endogenous mechanisms such as chap-
erone pathways to ensure proper and
rapid folding of nascent polypeptide
chains and degradation of improperly
folded proteins (Brandvold andMorimoto,
2015). The paper by Castellano and co-
workers presents a novel approach in
the use of a modified, yeast-specific
chaperone Hsp104 as a possible thera-
peutic to remodel amyloids in semen
and reduce HIV infectivity and transmis-
sion (Castellano et al., 2015). Hsp104 is
a disaggregase involved in the recovery
after stress-induced protein aggregation
in S. cerevisiae and the only cellular
component known to remodel amyloid
fibrils (Glover and Lindquist, 1998).
Hsp104 has been shown to have diverse
substrate specificity and can disaggre-
gate toxic oligomers, a pre-fibrillar state
capable of self-templating, as well as
amyloid fibrils formed from a large num-
ber of proteins (Shorter and Lindquist,
2004). The fact that its specificity toward
different amyloids can be modulated
by minor changes in the amino acid
sequence makes it a very promising
candidate for designing amyloid thera-
peutics (Jackrel and Shorter, 2015).
Castellano et al. describe in vitro
Hsp104 remodeling and aggregate clus-
tering of amyloid fibrils from proteolytic
fragments of prostatic acid phospha-
tase (PAP) and semenogelin 1 (SEM1).
PAP248-286 (SEVI) fibrils incubated with
Hsp104 were remodeled into non-amy-
loid aggregates with reduced
binding to the amyloid binding
dye Thioflavin-T (ThT). The
transformation of cross b
sheet-rich structures to amor-
phous aggregates was also
visualized by transmission
electron microscopy (TEM).
The remodeling does not
generate increased levels of
monomers and the resulting
non-amyloid aggregated ma-
terial had lost its seeding
capacity. Next, the authors
explore the remodeling
activity of an enhanced
variant of the disaggregase
Hsp104A503V that has previ-
ously been shown to remodel
TDP-43 and a-synuclein pro-
tein aggregates implicated in
frontotemporal lobar demen-
tia (FTLD), amyotrophic lateral
Figure 1. Hsp104 Mediated Clustering and Remodeling of Seminal
Amyloids
Hsp104 mediated remodeled aggregates can be degraded efficiently in the
presence of cellular proteases.
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sclerosis (ALS), and Parkin-
son’s disease, respectively.
Hsp104A503V reduced ThT
binding to SEVI fibrils by
50% after 2 hr incubation
with an EC50 of 36 nM, a
20-fold decrease compared
to wild-type Hsp104. Similar
results were observed with
an additional proteolytic frag-
ment from the same protein,
PAP85-120. The fibril remod-
eling activity of Hsp104 does
not appear to be conserved
between different amyloid
forming peptides in semen
because the semenogelin
(SEM145-107) fragment was
not remodeled by either
Hsp104 or the enhanced variant
(Figure 1).
In addition, Hsp104 was found to pro-
mote the formation of larger aggregates
of seminal amyloids in an ATP-inde-
pendent manner. The dual activity of
Hsp104 to either remodel fibrils into large
amorphous aggregates with less cross b
sheet-rich structure or cluster fibrils into
larger aggregates appeared to be fibril
specific. Various shorter versions of the
protein analyzed for remodel and clus-
tering activity showed that amyloid re-
modeling requires Hsp104 to be in the
active hexameric form as well as ATP hy-
drolysis whereas the backbone of Hsp104
is sufficient for the clustering of amyloid
into larger aggregates. Further, the re-
modeled amorphous material was readily
degraded by the bacterial peptidase,
ClpP associated with HAP, a modified
Hsp104 variant. A cell-based assay was
used to evaluate the effect of various
Hsp104 variants on seminal fibril remodel-
ing, clustering, degradation and HIV
infectivity. As expected, the remodeled
material with less b sheet-rich protein ag-
gregates had reduced HIV infectivity and
treatment with the enhanced Hsp104
yielded the most significant reduction.
Interestingly, fibrils that are not remodeled
by Hsp104 but clustered together forming
larger aggregates also show reduced
HIV infectivity positively correlated with
aggregation size.
How do we apply this information to
design therapeuticmolecules, specifically
to treat amyloid diseases? The large size
of the disaggregase and lack of prior
knowledge about manufacturing and
administering large protein complexes
makes it difficult to consider Hsp104 as
a therapeutic candidate against amyloids.
Further, ensuring proper assembly of
the active chaperone complex in the com-
plex milieu of aggregating proteins and
providing a constant supply of nucleo-
tides would be challenging.
Alternatively, we suggest two more
feasible strategies to design and develop
therapeutic molecules against amyloids:
grafting the substrate binding do-
main to therapeutic scaffolds and engi-
neering amyloid-specific nanomachine
disaggregators.
Hsp104 is a suitable candidate for
grafting the substrate binding domain
to therapeutic scaffolds because these
studies show that Hsp104 is capable of
binding a wide range of substrates in a
sequence-independent or conformation-
dependent manner. A large fraction of
the potentiated variants that bind unnatu-
ral substrates only show alterations in
their ATPase activity and altered inter-
domain communication. Therefore, if the
precise substrate-binding domain is iden-
tified, transferring this to an antibody or
smaller more stable structure like the
nanobody or single chain antibody (Per-
chiacca et al., 2012) could allow genera-
tion of new class of potent amyloid-spe-
cific conformational binders.
Hsp104 is also a suitable candidate
for engineering amyloid-specific nanoma-
chine disaggregators because it can both
bind to a diverse group of misfolded
structures and remodel them. To do this,
Hsp104 uses the peristaltic mechanism
of substrate threading facilitated by a
sequential hydrolysis of ATP
molecules and an associ-
ated re-arrangement of the
different domains in the active
hexamer. If this movement is
replicated in a monomeric
protein with 2 domains, one
for binding substrates tran-
siently and the other to induce
conformational change in the
substrate-bound complex,
then it could be engineered
to bind amyloid substrates
and induce its remodeling.
Hsp104 variants that fail to
multimerize but retain sub-
strate binding and ATPase
activity (partial or complete)
could be good scaffolds to
begin with. Other molecules like the prolyl
isomerases SlyD and FkpA or the TolA
binding phage protein g3p could also
function as good scaffolds (Schmidpeter
and Schmid, 2015). All these molecules
trigger conformational changes in their
domains by a cis-trans proline isomeriza-
tion. This would also eliminate the need
for ATP to fuel the conformational switch.
Interestingly, the phage protein g3p binds
a large number of amyloid proteins in
a conformation-dependent manner with
very high affinity (Krishnan et al., 2014)
(Figure 2).
S. cerevisiae harbors a large number of
self-replicating protein aggregates. These
aggregates act as heritable epigenetic
elements that allow the fungi to survive
in diverse and often harsh environmental
conditions. The chaperone networks in
these organisms have been evolved
to maintain protein aggregates without
causing any detrimental effects to the
cells. With most traditional approaches
to make therapeutic molecules against
amyloids failing over the last two de-
cades, we should probably realign our
approach to select therapeutic molecules
based on conformational binders like the
metazoan Hsp104 that remodel amyloids
without any toxic side effects.
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Griselimycin (GM), a natural product isolated a half century ago, is having a bit of a renaissance. After being
known for more than 50 years, it is now being pursued as a treatment for tuberculosis. With the new mech-
anism of action, excellent in vitro and in vivo activity against sensitive and drug-resistant Mycobacterium
tuberculosis, and the improved pharmacokinetic properties, the cyclohexyl derivative of GM demonstrates
a high translational potential.
Tuberculosis (Tb), caused by Mycobacte-
rium tuberculosis (Mtb), is one of the major
global infectious diseases. Even though
9 million cases were reported in 2013,
with 1.5 million deaths per year (World
Health Organization, 2014), the treatment
of the infection is managed by old drugs
discovered in the 1950s and 1960s. The
regimenstartswitha fourdrugcombination
consisting of isoniazid, rifampicin, etham-
butol, and pyrazinamide for 2 months, fol-
lowed by the combination of isoniazid and
rifampicin for another4months. In2012,af-
ter some 40 years of almost no progress in
anti-Tb drug discovery, two new
drugs were approved: bedaquiline,
which targets the ATP synthase, and
delamanid, a nitroimidazole that re-
leases toxic nitric oxidewhenmetab-
olized. Bothbedaquiline anddelama-
nid are active against multidrug-
resistant (MDR) tuberculosis and
thus are able to tackle the huge resis-
tance problem. Some additional
compounds are in the pipeline in
different stages of clinical trials.
Along with the urgent need to
solve the problems with MDR and
extremely drug-resistant (XDR)
strains, there is also a real necessity to
find new antibiotics, which will allow a far
shorter treatment with a lower number of
drugs. Moreover, the new anti-infectives
must work well with other drugs because
Tb is often associated with HIV, especially
in sub-Saharan Africa (where there were
approximately 350,000 death in 2013),
and diabetes. Finally, because Tb occurs
mostly in low-income countries, the new
drugs should be cheap. The bottom line
is that new, effective, safe, and cheap
anti-Tb drugs with different mechanism
of action must be developed to address
the significant challenge that Tb poses
for public health.
Most molecules that are currently being
explored as anti-Tb treatments options
fall into the small molecule category,
although there is an increasing interest in
exploring natural products in this context.
Cyclic peptide griselimycin (GM, Figure 1)
was isolated in the 1960s from Strepto-
myces and its antibacterial and antimyco-
bacterial activity was evaluated in the
early 1970s (Terlain and Thomas, 1971a,
1971b). The early work established that
GM has unfavorable pharmacokinetic
properties, and, given that rifam-
picin was approved at that time,
the development of GM as an anti-
Tb drug was terminated. Recently,
Rolf Mu¨ller and colleagues decided
to revisit GM, given its high activity
(Kling et al., 2015). First, they
increased the metabolic stability of
GM by alkylation of the proline resi-
due in position 8. A cyclohexyl GM
(CGM) derivative, obtained via a
newly developed total synthesis,
was metabolically stable, and the
increased lipophilicity enhanced
the penetration of the thick
Figure 1. Structural Formula of Griselimycin
Alkylation of the proline ring in position 8 reveals an improve-
ment of the pharmacokinetics.
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